



09-03-04

JHV

PATENT
DOCKET NO. JHV-028.01

In re Application of:

Gallagher, M., et al.

Application No: 10/722,357

Filed: November 24, 2003

For: Target for Therapy of Cognitive
Impairment

Art Unit: 1641

Examiner: Not Yet Known


Attorney Docket: JHV-028.01

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Number: EV 327702601 US, postage prepaid, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450 on September 2, 2004.


Kristen M. Williams

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the documents listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Because this application was filed after June 30, 2003, copies of the U.S. patents are not enclosed. However, a copy of the foreign patent documents and copies of the references are also being submitted.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or
- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that **[check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]**:


- ☐ 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- ☐ 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

In addition, as a courtesy to the Examiner, a copy of the International Search Report for Applicants' copending application PCT/US03/38191 is also enclosed. If the Examiner has any questions, or if a teleconference would advance the instant application toward allowance, the Examiner is urged to telephone the undersigned at 202-261-7356.

Date: September 2, 2004

Customer No.: 25181
Patent Group
Foley Hoag LLP
155 Seaport Boulevard
Boston, MA 02210
617-832-1000
617-832-7000 (FAX)

Respectfully Submitted,

A handwritten signature in black ink, appearing to read "Gillian M. Fenton", is written over a horizontal line.

Gillian M. Fenton
Reg. No. 36,508
Attorney for Applicant

Form PTO-1449

INFORMATION DISCLOSURE CITATION**IN AN APPLICATION***(Use several sheets if necessary)*

Docket Number (Optional)

JHV-028.01

Application Number

10/722,357

Applicant

Gallagher, Michela et al.

Filing Date

November 24, 2003

Group Art Unit

1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1 US 2002/0048746 A1	April 25, 2002	Model For Alzheimer's Disease and Other Neurodegenerative Diseases			July 31, 2001
	A2 4,103,085	July 25, 1978	7-SYN- <i>α</i> -ALKOXY- IMINOFURYLACETAMIDO- 3-(2-CARBOXY-ALYKL-2,3- DIHYDRO-S-TRIAZOLO[4,3- B]PYRIDAZIN-3-ON-6- YLTHIOMETHYL)-3- CEPHEM-4-CARBOXYLIC ACIDS			February 24, 1977
	A3 5,162,573	November 10, 1992	VALPROIC AND (E)-2- VALPROENOIC ACID DERIVATIVES, AND PAHRMACEUTICAL COMPOSITIONS THEREFROM			June 17, 1987

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
	B1 WO 02/08449 A2	31 January 2002	PCT	C12Q 1/00			

OTHER DOCUMENTS*(Including Author, Title, Date, Pertinent Pages Etc.)*

EXAMINER		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.